论文部分内容阅读
本研究的目的是以严格对照的临床研究方法,采用国际上评定短程化疗效果通用的复发率和总失败率指标,评定小于利福平剂量的利福定治疗初治涂阳肺结核的效果。经过4年远期随访,发现应用利福平1/2剂量的利福定的复发率和总失败率均分别显著地高于对照利福平。作者们认为,利福定在无实验室和临床反复的严格的科学研究证实其确切疗效和有效的、合理的剂量以前,难于在实际治疗工作中正式使用。
The aim of this study was to evaluate the efficacy of rifampin in the treatment of newly diagnosed smear-positive pulmonary tuberculosis with rifampicin at a dose less than rifampin using a rigorous and controlled clinical study using the internationally accepted standard of recurrence and total failure rates for short-term chemotherapy. After 4 years of follow-up, it was found that the relapse rate and the total failure rate of rifampin using 1/2 dose of rifampicin were significantly higher than that of the control rifampin, respectively. The authors argue that it was difficult to make it routinely used in real-life therapeutics until Rifidite has been tested in laboratory and clinically repeated rigorous scientific studies to confirm its exact efficacy and effective and reasonable dosage.